Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 8;71(4):599–611. doi: 10.1002/art.40753

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Spondyloarthritis Research Consortium of Canada (SPARCC) magnetic resonance imaging (MRI) index spine scores (A) and serum C‐reactive protein (CRP) levels (B) among patients treated with placebo (PBO), ixekizumab every 2 weeks (IXEQ2W), or ixekizumab every 4 weeks (IXEQ4W) through 16 weeks. † = P < 0.01; ‡ = P < 0.001, all versus placebo by analysis of covariance (ANCOVA) and least squares mean (LSM) (A) or mixed‐effects model of repeated measures (MMRM) and LSM (B). Only SPARCC MRI spine score analyses at week 16 were included in the prespecified multiple testing strategy. Values shown are the LSM ± SE. N = number of patients in the analysis population; Nx = number of patients in the MRI addendum population.